First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - ScienceDirect

$ 13.00

4.5 (351) In stock

Figure 1 from Molecular Pathways: Fatty Acid Synthase

First-in-human study of the safety, pharmacokinetics, and

Lipids and cancer: Emerging roles in pathogenesis, diagnosis and

PDF) Metabolic dysregulation and emerging therapeutical targets

SciELO - Brasil - Fatty acid synthase as a potential new

FASN inhibitor TVB-3166 prevents S-acylation of the spike protein

Fatty Acid Synthase Inhibitor - an overview

PDF) Targeting fatty acid uptake and metabolism in cancer cells: A

Lipids and cancer: Emerging roles in pathogenesis, diagnosis and